Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations

阿法替尼 奥西默替尼 T790米 医学 肺癌 肿瘤科 表皮生长因子受体 内科学 人口 克拉斯 吉非替尼 癌症研究 癌症 埃罗替尼 结直肠癌 环境卫生
作者
Kartik Sehgal,Deepa Rangachari,Paul A. VanderLaan,Susumu Kobayashi,Daniel B. Costa
出处
期刊:Oncologist [Wiley]
卷期号:26 (4): 281-287 被引量:17
标识
DOI:10.1002/onco.13537
摘要

Abstract The optimal management of advanced non-small cell lung cancer (NSCLC) with noncanonical epidermal growth factor receptor (EGFR) mutations (i.e., exon 19 deletion and exon 21 L858R) is constrained by the heterogeneous behavior of individual uncommon mutations and limited prospective clinical data in this setting. Despite encouraging results with osimertinib from a recently published phase II trial from South Korea, afatinib remains the only currently approved drug for patients with tumors harboring uncommon EGFR mutations (i.e., S768I, L861Q, and/or G719X). When used at the standard dose of 40 mg daily, afatinib is associated with significant rates of treatment-related adverse events, leading to frequent dose reductions and treatment discontinuations. We report a case of a woman with advanced NSCLC harboring EGFR-G719A mutation treated with afatinib (at an off-label pulse dose strategy that merits further evaluation in prospective studies) with sustained partial response for 20 months with manageable expected toxicities. Subsequent disease progression was mediated by off-target pan-EGFR inhibitor (including osimertinib)–resistant KRAS mutation and not by acquisition of EGFR-T790M. We further present the current state of evidence in the literature behind use of first-, second-, and third-generation tyrosine kinase inhibitors and summarize the evolving spectrum of activity ascribed to osimertinib (and newer EGFR inhibitors with a more favorable therapeutic window and intracranial penetration) in this population of patients with advanced NSCLC and uncommon EGFR mutations. Key Points Uncommon EGFR mutations characterize a heterogeneous group of patients with advanced non-small cell lung cancer (NSCLC). Afatinib is the only currently U.S. Food and Drug Administration–approved drug for management of advanced NSCLC with uncommon EGFR mutations (S768I, L861Q, and/or G719X). Afatinib treatment at 40 mg daily is associated with high rates of adverse events and dose reductions; alternative strategies including pulse intermittent dosing should be evaluated prospectively. Osimertinib (with favorable safety profile and intracranial penetration) has shown promising results in this population in a phase II trial from South Korea; additional trials are ongoing.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
卖鱼的乌鸦完成签到,获得积分10
1秒前
3秒前
4秒前
4秒前
马俣辰完成签到,获得积分10
4秒前
兔先生发布了新的文献求助10
4秒前
泡面完成签到 ,获得积分10
4秒前
聪聪完成签到,获得积分10
4秒前
YUYUYU应助hyq008采纳,获得10
5秒前
777777发布了新的文献求助30
6秒前
6秒前
酷波er应助生椰拿铁采纳,获得10
7秒前
娜娜发布了新的文献求助10
9秒前
迅哥发布了新的文献求助10
9秒前
科目三应助BALANCE采纳,获得10
10秒前
压寨猫夫人完成签到,获得积分10
10秒前
NexusExplorer应助liuyac采纳,获得10
11秒前
追寻紫安完成签到,获得积分10
12秒前
科研菜鸟完成签到,获得积分10
14秒前
孙玉发布了新的文献求助10
16秒前
惜寒完成签到 ,获得积分10
18秒前
19秒前
李爱国应助ljh采纳,获得10
20秒前
22秒前
leoooo发布了新的文献求助10
25秒前
生椰拿铁发布了新的文献求助10
25秒前
28秒前
沈小柠檬发布了新的文献求助10
28秒前
28秒前
rubbish发布了新的文献求助10
32秒前
自然可乐发布了新的文献求助10
32秒前
昂叔的头发丝儿完成签到,获得积分10
32秒前
ljh发布了新的文献求助10
33秒前
35秒前
38秒前
周冬华完成签到,获得积分10
38秒前
岛err发布了新的文献求助10
39秒前
yuko完成签到,获得积分10
39秒前
憨憨完成签到 ,获得积分10
40秒前
41秒前
高分求助中
Evolution 10000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Foreign Policy of the French Second Empire: A Bibliography 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
China's Relations With Japan 1945-83: The Role of Liao Chengzhi 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3148036
求助须知:如何正确求助?哪些是违规求助? 2799034
关于积分的说明 7833337
捐赠科研通 2456217
什么是DOI,文献DOI怎么找? 1307159
科研通“疑难数据库(出版商)”最低求助积分说明 628077
版权声明 601620